Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
B 15.49 -1.46% -0.23
ZGNX closed down 1.46 percent on Friday, September 24, 2021, on 41 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ZGNX trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Narrow Range Bar Range Contraction -1.46%
NR7 Range Contraction -1.46%
Stochastic Reached Overbought Strength -1.46%
Upper Bollinger Band Walk Strength -1.46%
Inside Day Range Contraction -1.46%
Overbought Stochastic Strength -1.46%
Upper Bollinger Band Touch Strength -1.46%
Older End-of-Day Signals for ZGNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Zogenix, Inc. Description

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Pain Opioid Schizophrenia Symptoms Chronic Pain Nervous System Disorders Central Nervous System Disorders Neurochemistry Morphinans Ketones Migraine Bipolar Disorder European Union Cell Signaling Headache Retail Pharmacies Treatment Of Migraine Hydrocodone Treatment Of Central Nervous System Disorders Severe Chronic Pain Indoles Moderate To Severe Chronic Pain Pharmaceutical Distributors Relday Triptans

Is ZGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.69
52 Week Low 13.0143
Average Volume 698,899
200-Day Moving Average 18.37
50-Day Moving Average 15.20
20-Day Moving Average 15.02
10-Day Moving Average 15.22
Average True Range 0.61
ADX 20.4
+DI 28.10
-DI 11.92
Chandelier Exit (Long, 3 ATRs) 14.29
Chandelier Exit (Short, 3 ATRs) 15.96
Upper Bollinger Bands 15.81
Lower Bollinger Band 14.24
Percent B (%b) 0.8
BandWidth 10.48
MACD Line 0.15
MACD Signal Line 0.01
MACD Histogram 0.1349
Fundamentals Value
Market Cap 862.38 Million
Num Shares 55.7 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -4.67
Price-to-Sales 158.59
Price-to-Book 2.91
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.31
Resistance 3 (R3) 16.40 16.21 16.17
Resistance 2 (R2) 16.21 16.00 16.17 16.13
Resistance 1 (R1) 15.85 15.87 15.76 15.76 16.08
Pivot Point 15.67 15.67 15.62 15.62 15.67
Support 1 (S1) 15.31 15.46 15.21 15.22 14.90
Support 2 (S2) 15.12 15.33 15.08 14.85
Support 3 (S3) 14.76 15.12 14.81
Support 4 (S4) 14.67